Company Overview
Company Type: Public Company
Website: izocorp.com
Number of Employees: -
Ticker: IZO (CNSX)
Year Founded: 2016


Business Description
Izotropic Corporation, a medical device company, develops and commercializes diagnostic products for detecting breast cancers. It develops and commercializes IzoView, a 360-degree computed tomography imaging system designed for breast imaging. The company was incorporated in 2016 and is headquartered in Surrey, Canada.

Financial Information (Currency: CAD, in mm) 
Market Capitalization
12.9
EBITDA
(4.7)
Total Enterprise Value
14.8
TEV/EBITDA
NM
EBIT
(4.7)
Cash & ST Invst.
0.2
P/Diluted EPS Before Extra
NM
Net Income
(5.1)
Total Debt
2.1
Price/Tang BV
NM
Capital Expenditure
0.0
Total Assets
0.4
Total Debt/EBITDA
NM




Currency in CAD in mm, LTM as of Jul-31-2023 TEV and Market Cap are calculated using a close price as of Oct-04-2023

Key Professionals
Name
Title
Thast, Robert Louis
Founder, Interim CEO & Chairman
Proceviat, Ralph F.
Director & Interim CFO
Achkire, Younes 
Executive VP of Product Engineering & COO
Sodagar, Ali Reza
Legal Advisor & Independent Director
Hernandez, Andrew M.
Head of Imaging Technology
Thast, Jaclyn 
Operations Manager & Corporate Secretary

Key Board Members
Name
Title
Thast, Robert Louis
Founder, Interim CEO & Chairman
Proceviat, Ralph F.
Director & Interim CFO
Sodagar, Ali Reza
Legal Advisor & Independent Director
Abbey, Craig 
Member of Advisory Board
Boone, John M.
Independent Director
Burkett, George 
Member of the Advisory Board
Lindfors, Karen K.
Member of Advisory Board
Nosratieh, Anita 
Member of Advisory Board
Pelc, Norbert J.
Senior Development & Technology Advisor and Member of Advisory Board
Shakeri, Shadi Aminololama
Member of Advisory Board & Clinical Consultant - Commercialization Team
Shimasaki, Craig D.
Medical Device Business Consultant & Member of Advisory Board
Siewerdsen, Jeff 
Member of Scientific Advisory Board


Primary Industry Classification
Health Care Equipment


Primary Office Location
800 – 15355 24th Avenue Suite 424 | Surrey, BC | V4A 2H9 | Canada
Phone: 833-496-2677   

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.24
Market Cap (mm)
12.9
Open
 0.23
Shares Out. (mm)
54.7
Previous Close
 0.24
Float %
88.2%
Change on Day
0.04
Shares Sold Short (mm)
-
Change % on Day
17.5%
Dividend Yield %
-
Day High/Low
 0.24/ 0.23
Diluted EPS Excl. Extra Items
(0.10)
52 wk High/Low
 0.86/ 0.18
P/Diluted EPS Before Extra
NM
Volume (mm)
0.0013
Avg 3M Dly Vlm (mm)
0.02
Beta 5Y
2.74


 
Delayed Quote** | Last Updated on Oct-04-2023 12:00 AM (GMT-5)
CNSX:IZO - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Isotropic Imaging Corp.

United States and Canada
-
-
-
-
Izotropic Imaging Corp.

United States and Canada
-
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Sep-13-2023
Sep-20-2023
Private Placement
Target
Izotropic Corporation (CNSX:IZO)


0.53
Nov-10-2022
Nov-10-2022
Private Placement
Target
Izotropic Corporation (CNSX:IZO)


0.75
Mar-30-2022
Apr-04-2022
Private Placement
Target
Izotropic Corporation (CNSX:IZO)


1.64
Dec-09-2020
Dec-09-2020
Private Placement
Target
Izotropic Corporation (CNSX:IZO)


1.33
Oct-20-2020
Oct-30-2020
Private Placement
Target
Izotropic Corporation (CNSX:IZO)


3.05
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-27-2023
Product-Related Announcements
Izotropic Corporation Confirms Fda Pre-Submission Meeting Date with U.S. Food and Drug Administration
Sep-21-2023
Product-Related Announcements
Izotropic Corporation Files Class II Pre-Submission with FDA & Releases Details on Predicate Devices
Sep-20-2023
Private Placements
Izotropic Corporation announced that it has received CAD 0.710331 million in funding
Sep-13-2023
Private Placements
Izotropic Corporation announced that it expects to receive CAD 0.5 million in funding
Jun-08-2023
Executive Changes - CEO
Izotropic Corporation Announces John McGraw Has Resigned as Chief Executive Officer


Advisors
Most Recent Auditor
Dale Matheson Carr-Hilton LaBonte LLP
Public Offering Advisors
Clark Wilson LLP, Dale Matheson Carr-Hilton LaBonte LLP


Most Recent Auditor
Dale Matheson Carr-Hilton


Last 10 Investment Research Documents
No Investment Research returned. This can be caused by entitlement settings or your template settings.


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Thast, Robert Louis

3,913,167

7.15

0.8

Jun-21-2023


Boone Ph.D., John M.

1,000,000

1.83

0.2

Nov-17-2022


Thast, Jaclyn 

530,000

0.97

0.1

Nov-03-2022


Sodagar, Ali Reza

429,000

0.78

0.1

Nov-17-2022


McGraw M.Sc., Ph.D., John 

400,000

0.73

0.1

Nov-17-2022


Proceviat CPA, Ralph F.

100,000

0.18

0.0

Nov-17-2022


Tokman, Alexander Y.

100,000

0.18

0.0

Nov-17-2022


AI Artificial Intelligence Ventures Inc.

7,000

0.01

0.0

Aug-31-2022


NVWM LLC

1,500

0.00

0.0

Jun-30-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Thast, Robert Louis
3,913,167
20,000

Top Sellers
No Top Sellers data available.


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
Date/Time
Headline
Source
Sep-06
IZO Izotropic files presubmission application for IzoView
Canada StockWatch


Company Coverage
This company is not on any Coverage List.


Upcoming Events
Date/Time
Type
Dec-21-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Sep-27-2023
-
Izotropic Corporation (CNSX:IZO)
SEDAR
Statement of Executive Compensation
208 KB
Sep-27-2023
Jul-31-2023
Izotropic Corporation (CNSX:IZO)
SEDAR
Interim Financial Statements
439 KB
Sep-27-2023
-
Izotropic Corporation (CNSX:IZO)
SEDAR
News Releases
144 KB
Sep-21-2023
-
Izotropic Corporation (CNSX:IZO)
SEDAR
Material Change Report
292 KB
Sep-21-2023
-
Izotropic Corporation (CNSX:IZO)
SEDAR
News Releases
36 KB
Sep-21-2023
-
Izotropic Corporation (CNSX:IZO)
SEDAR
News Releases
50 KB
Sep-13-2023
-
Izotropic Corporation (CNSX:IZO)
SEDAR
News Releases
153 KB
Aug-30-2023
Apr-30-2023
Izotropic Corporation (CNSX:IZO)
SEDAR
Annual Financial Statements
692 KB
Jun-27-2023
-
Izotropic Corporation (CNSX:IZO)
SEDAR
News Releases
155 KB
Jun-20-2023
-
Izotropic Corporation (CNSX:IZO)
SEDAR
News Releases
161 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Thast, Robert Louis (Founder, Interim CEO & Chairman)
Jun-21-2023
Common Shares
20,000
6,043
Open Market Acquisition
0.51
Multiple
Thast, Robert Louis (Founder, Interim CEO & Chairman)
Dec-12-2022
Common Shares
8,500
6,287
Open Market Acquisition
0.22
Multiple
-
Dec-12-2022
Common Shares
5,000
3,669
Open Market Acquisition
-
Exchange Announcement
-
Dec-12-2022
Common Shares
2,500
1,885
Open Market Acquisition
-
Exchange Announcement
-
Dec-12-2022
Common Shares
1,000
734
Open Market Acquisition
-
Exchange Announcement
Thast, Robert Louis (Founder, Interim CEO & Chairman)
Dec-05-2022
Common Shares
18,000
15,600
Open Market Acquisition
0.47
Multiple
-
Dec-05-2022
Common Shares
8,500
7,412
Open Market Acquisition
-
Exchange Announcement
-
Dec-05-2022
Common Shares
9,500
8,188
Open Market Acquisition
-
Exchange Announcement
Sodagar, Ali Reza (Legal Advisor & Independent Director)
Sep-20-2022
Common Shares
(200,000)
0
Derivative Exercise and Sale
-
Multiple
-
Sep-20-2022
Common Shares
200,000
20,593
Derivative Exercise
-
Exchange Announcement
-
Sep-20-2022
Common Shares
(200,000)
(20,593)
Sale
-
Exchange Announcement
Proceviat CPA, Ralph F. (Director & Interim CFO)
Jan-26-2022
Common Shares
25,000
-
Other Acquisition
New
Multiple
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Thast, Robert Louis
Founder, Interim CEO & Chairman
604.542.9458
-
bthast@telus.net
Proceviat, Ralph F.
Director & Interim CFO
(604) 220-6297
-
rproceviat@leveltencorp.com
Sodagar, Ali Reza
Legal Advisor & Independent Director
833-496-2677
-

Abbey, Craig 
Member of Advisory Board
833-496-2677
-

Boone, John M.
Independent Director
833-496-2677
-

Burkett, George 
Member of the Advisory Board
833-496-2677
-

Lindfors, Karen K.
Member of Advisory Board
833-496-2677
-
-
Nosratieh, Anita 
Member of Advisory Board
833-496-2677
-

Pelc, Norbert J.
Senior Development & Technology Advisor and Member of Advisory Board
833-496-2677
-

Shakeri, Shadi Aminololama
Member of Advisory Board & Clinical Consultant - Commercialization Team
833-496-2677
-

Shimasaki, Craig D.
Medical Device Business Consultant & Member of Advisory Board
833-496-2677
-
-
Siewerdsen, Jeff 
Member of Scientific Advisory Board
833-496-2677
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Thast, Robert Louis
Founder, Interim CEO & Chairman
604.542.9458
-
bthast@telus.net
Proceviat, Ralph F.
Director & Interim CFO
(604) 220-6297
-
rproceviat@leveltencorp.com
Achkire, Younes 
Executive VP of Product Engineering & COO
833-496-2677
-

Sodagar, Ali Reza
Legal Advisor & Independent Director
833-496-2677
-

Hernandez, Andrew M.
Head of Imaging Technology
833-496-2677
-

Thast, Jaclyn 
Operations Manager & Corporate Secretary
833-496-2677
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
